This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Vertex Pharmaceuticals (VRTX) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $460, moving -1.06% from the previous trading session.
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day.
Is Most-Watched Stock Vertex Pharmaceuticals Incorporated (VRTX) Worth Betting on Now?
by Zacks Equity Research
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Vertex Stock Loses Around $3B in 3 Months: Buy the Dip or Steer Clear?
by Kinjel Shah
VRTX is a good stock to have in one's portfolio based on its strong overall financial performance and robust pipeline progress.
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $470.78, indicating a -0.07% shift from the previous trading day.
Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report?
by Zacks Equity Research
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
The Zacks Analyst Blog Highlights Texas Instruments, Union Pacific, Vertex Pharmaceuticals, Tile Shop and Gencor
by Zacks Equity Research
Texas Instruments, Union Pacific, Vertex Pharmaceuticals, Tile Shop and Gencor are included in this Analyst Blog.
Top Stock Reports for Texas Instruments, Union Pacific & Vertex Pharmaceuticals
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments Incorporated (TXN), Union Pacific Corporation (UNP) and Vertex Pharmaceuticals Incorporated (VRTX), as well as two micro-cap stocks Tile Shop Holdings, Inc. (TTSH) and Gencor Industries, Inc. (GENC).
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?
by Sundeep Ganoria
Despite gaining regulatory approvals in many countries for the first ever CRISPR-based gene therapy, investors should remain wary of investing in CRISPR Therapeutics' (CRSP) early-stage pipeline.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
BMY vs. VRTX: Which Stock Is the Better Value Option?
by Zacks Equity Research
BMY vs. VRTX: Which Stock Is the Better Value Option?
Vertex (VRTX) Stock Outperforms Industry YTD: Here's Why
by Zacks Equity Research
Vertex's (VRTX) CF sales are expected to remain strong despite a slight slowdown in the growth rate. Casgevy and suzetrigine (if approved) are set to provide the necessary diversification from the CF franchise.
The Zacks Analyst Blog Vertex Pharmaceuticals CRISPR and Moderna
by Zacks Equity Research
Vertex Pharmaceuticals CRISPR and Moderna are included in this Analyst Blog.
Top Research Reports for NVIDIA, Home Depot & Vertex Pharmaceuticals
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), The Home Depot, Inc. (HD) and Vertex Pharmaceuticals Incorporated (VRTX), as well as a micro-cap stock Moving iMage Technologies, Inc. (MITQ).
Here's How to Play Vertex (VRTX) Stock After Q2 Loss, Price Dip
by Kinjel Shah
Vertex (VRTX) is a great stock to have in one's portfolio based on its strong overall financial performance and robust pipeline progress.
Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down
by Zacks Equity Research
Editas (EDIT) reports lower-than-expected second-quarter 2024 results as both earnings and revenues miss estimates. The stock falls 12.2%.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
CRISPR Therapeutics (CRSP) Q2 Loss Wider Than Expected
by Zacks Equity Research
CRISPR Therapeutics (CRSP) incurs a wider-than-expected loss in the second quarter of 2024. The commercial launch of CRISPR-based gene therapy, Casgevy, is progressing well.
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Compared to Estimates, Vertex (VRTX) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Vertex (VRTX) Q2 Loss Wider Than Expected, '24 Sales View Raised
by Zacks Equity Research
Vertex (VRTX) incurs a wider-than-expected loss in the second quarter while sales come in line with estimates. Vertex raises its full-year product revenue guidance.
Should You Invest in Vertex (VRTX) Based on Bullish Wall Street Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Vertex (VRTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Vertex Pharmaceuticals (VRTX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of -11.57% and 0.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?